PTC Therapeutics (PTCT) Misses Q1 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
May 3, 2022 4:01 PM EDT- $149 million total revenue representing impressive 26% year-over-year growth
- Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease
- CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch
SOUTH PLAINFIELD, N.J., May 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2022.
"We are continuing to build a robust... More
